Bringing next generation single-use sensor technologies to the life science market
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.
Pall Corporation has partnered with Broadley-James Corporation to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors. With applications across upstream and downstream unit operations, the sensor will be integrated into Pall Biotech’s single-use (SU) technologies, as well as other commercially available bioprocessing platforms.
“Pall’s single-use bioprocessing know-how and Broadley-James’ expertise in sensor development have proven complementary in addressing critical customer pain points in modern bioprocessing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In particular, the new single-use pH sensor solution allows us to offer customers the robustness of traditional sensor technologies integrated into their single-use systems.”
The novel SU pH sensors leverage widely accepted glass electrochemical technology, the only method that meets international standards for pH measurement. The design includes a calibrated buffer storage environment for the sensor to eliminate previous constraints during pre-integration of glass pH sensors into consumables. Users will be able to operate in closed systems, without sacrificing performance.
“Customers currently rely on calibration data gathered before the sensor is sterilized, which can affect the measurement accuracy,” said Robert Garrahy, Vice-President at Broadley-James. “Our patent-pending new storage solutions design features a known pH buffer, enabling robust pre-use calibration. By pairing trusted technology with cutting-edge design, we are able to offer the best balance of risk reduction and performance.”
The Broadley-James single-use probe and flow cell pH sensors are currently in beta testing and when launched will be available exclusively through Pall Biotech. Parallel technical and process development support is also available to optimize use of this new technology.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance